Barrett's oesophagus

The Lancet

Volumn 373, Issue 9666, 2009, Pages 850-861

  Shaheen, Nicholas J ^a   Richter, Joel E ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL FEATURE; DYSPLASIA; ENDOSCOPIC THERAPY; ESOPHAGUS RESECTION; GASTROINTESTINAL ENDOSCOPY; HUMAN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 61349116213     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60487-6     Document Type: Review

References (139)

1. Spechler S.J. Barrett's esophagus. N Engl J Med 346 (2002) 836-842
2. Shaheen N., and Ransohoff D.F. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287 (2002) 1972-1981
3. Eisen G.M., Sandler R.S., Murray S., and Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 92 (1997) 27-31
4. Sampliner R.E., and the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 97 (2002) 1888-1895
5. Shaheen N.J., Provenzale D., and Sandler R.S. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol 97 (2002) 1319-1327
6. Sharma P., McQuaid K., Dent J., et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 127 (2004) 310-330
7. Wang K.K., Sampliner R.E., and the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103 (2008) 788-797
8. Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 63 (2006) 570-580
9. Playford R.J. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 55 (2006) 442
10. Vakil N., van Zanten S.V., Kahrilas P., Dent J., Jones R., and the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101 (2006) 1900-1920
11. Sharma P., Morales T.G., Bhattacharyya A., Garewaç S., and Sampliner R.E. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 92 (1997) 2012-2016
12. Spechler S.J. Short and ultrashort Barrett's esophagus-what does it mean?. Semin Gastrointest Dis 8 (1997) 59-67
13. May A., Gossner L., Pech O., et al. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy 34 (2002) 604-610
14. Spechler S.J., Zeroogian J.M., Antonioli D.A., Wang H.H., and Goyal R.K. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344 (1994) 1533-1536
15. Wallner B., Sylvan A., Stenling R., and Janunger K.G. The Z-line appearance and prevalence of intestinal metaplasia among patients without symptoms or endoscopical signs indicating gastroesophageal reflux. Surg Endosc 15 (2001) 886-889
16. Morales T.G., Camargo E., Bhattacharyya A., and Sampliner R.E. Long-term follow-up of intestinal metaplasia of the gastric cardia. Am J Gastroenterol 95 (2000) 1677-1680
17. O'Connor J.B., Falk G.W., and Richter J.E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94 (1999) 2037-2042
18. Drewitz D.J., Sampliner R.E., and Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4·8 years. Am J Gastroenterol 92 (1997) 212-215
19. Shaheen N.J., Crosby M.A., Bozymski E.M., and Sandler R.S. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 119 (2000) 333-338
20. Schnell T.G., Sontag S.J., Chejfec G., et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120 (2001) 1607-1619
21. Overholt B.F., Lightdale C.J., Wang K.K., et al., on behalf of the International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62 (2005) 488-498
22. Weston A.P., Sharma P., Topalovski M., Richards R., Cherian R., and Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 95 (2000) 1888-1893
23. Cameron A.J., Zinsmeister A.R., Ballard D.J., and Carney J.A. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99 (1990) 918-922
24. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129 (2005) 1825-1831
25. Rex D.K., Cummings O.W., Shaw M., et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125 (2003) 1670-1677
26. Ward E.M., Wolfsen H.C., Achem S.R., et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 101 (2006) 12-17
27. Gerson L.B., Shetler K., and Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 123 (2002) 461-467
28. Voutilainen M., Sipponen P., Mecklin J.P., Juhola M., and Farkkila M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 61 (2000) 6-13
29. Conio M., Filiberti R., Blanchi S., et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 97 (2002) 225-229
30. Lin M., Gerson L.B., Lascar R., Davila M., and Triadafilopoulos G. Features of gastroesophageal reflux disease in women. Am J Gastroenterol 99 (2004) 1442-1447
31. Westhoff B., Brotze S., Weston A., et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 61 (2005) 226-231
32. Avidan B., Sonnenberg A., Schnell T.G., and Sontag S.J. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 47 (2002) 256-264
33. Cameron A.J. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 94 (1999) 2054-2059
34. Fass R., Hell R.W., Garewal H.S., et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 48 (2001) 310-313
35. Oberg S., DeMeester T.R., Peters J.H., et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 117 (1999) 572-580
36. Eloubeidi M.A., and Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol 33 (2001) 306-309
37. Locke G.R., Zinsmeister A.R., and Talley N.J. Can symptoms predict endoscopic findings in GERD?. Gastrointest Endosc 58 (2003) 661-670
38. Conio M., Filiberti R., Blanchi S., et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 97 (2002) 225-229
39. Chak A., Lee T., Kinnard M.F., et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 51 (2002) 323-328
40. Gerson L.B., Shetler K., and Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 123 (2002) 461-467
41. Gray M.R., Donnelly R.J., and Kingsnorth A.N. The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus. Gut 34 (1993) 727-731
42. Ritenbaugh C., Sampliner R., Aickin M., Garewal H., and Meyskens F. Risk factors for Barrett's oesophagus: a life history approach to behavioural assessment in the distant past. Eur J Cancer Prev 4 (1995) 459-468
43. Heath E.I., Canto M.I., Piantadosi S., et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99 (2007) 545-557
44. Romero Y., Cameron A.J., Schaid D.J., et al. Barrett's esophagus: prevalence in symptomatic relatives. Am J Gastroenterol 97 (2002) 1127-1132
45. Hampel H., Abraham N.S., and El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143 (2005) 199-211
46. Jacobson B.C., Somers S.C., Fuchs C.S., Kelly C.P., and Camargo Jr. C.A. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 354 (2006) 2340-2348
47. El-Serag H.B., Kvapil P., Hacken-Bitar J., and Kramer J.R. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 100 (2005) 2151-2156
48. Corley D.A., Kubo A., Levin T.R., et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 133 (2007) 34-41
49. Edelstein Z.R., Farrow D.C., Bronner M.P., Rosen S.N., and Vaughan T.L. Central adiposity and risk of Barrett's esophagus. Gastroenterology 133 (2007) 403-411
50. Wilson L.J., Ma W., and Hirschowitz B.I. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 94 (1999) 2840-2844
51. Stene-Larsen G., Weberg R., Larsen I.F., Bjørtuft O., Hoel B., and Berstad A. Relationship of overweight to hiatus hernia and reflux oesophagitis. Scand J Gastroenterol 23 (1988) 427-432
52. Bremner C.G., Lynch V.P., and Ellis Jr. F.H. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 68 (1970) 209-216
53. Iascone C., DeMeester T.R., Little A.G., and Skinner D.B. Barrett's esophagus: functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg 118 (1983) 543-549
54. Stein H.J., Hoeft S., and DeMeester T.R. Functional foregut abnormalities in Barrett's esophagus. J Thorac Cardiovasc Surg 105 (1993) 107-111
55. Vaezi M.F., and Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 111 (1996) 1192-1199
56. Avidan B., Sonnenberg A., Schnell T.G., and Sontag S.J. Gastric surgery is not a risk for Barrett's esophagus or esophageal adenocarcinoma. Gastroenterology 121 (2001) 1281-1285
57. Dvorak K., Payne C.M., Chavarria M., et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 56 (2007) 763-771
58. Buttar N.S., Wang K.K., Leontovich O., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122 (2002) 1101-1112
59. Chen X., Li N., Wang S., et al. Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis 23 (2002) 2095-2102
60. Labenz J., and Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?. Gut 41 (1997) 277-280
61. Maaroos H.I., Vorobjova T., Sipponen P., et al. An 18-year follow-up study of chronic gastritis and Helicobacter pylori association of CagA positivity with development of atrophy and activity of gastritis. Scand J Gastroenterol 34 (1999) 864-869
62. Vaezi M.F., Falk G.W., Peek R.M., et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 95 (2000) 2206-2211
63. El-Serag H.B., and Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 43 (1998) 327-333
64. Jovov B., Van Itallie C.M., Shaheen N.J., et al. Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance. Am J Physiol Gastrointest Liver Physiol 293 (2007) G1106-G1113
65. Siahpush S.H., Vaughan T.L., Lampe J.N., et al. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 16 (2007) 2387-2395
66. Gough M.D., Ackroyd R., Majeed A.W., and Bird N.C. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important?. Am J Gastroenterol 100 (2005) 1012-1018
67. Kala Z., Dolina J., Marek F., and Izakovicova H.L. Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus. J Hum Genet 52 (2007) 527-534
68. Phillips R.W., Frierson Jr. H.F., and Moskaluk C.A. CDX2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 27 (2003) 1442-1447
69. Liu T., Zhang X., So C.K., et al. Regulation of CDX2 expression by promoter methylation, and effects of CDX2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 28 (2007) 488-496
70. Pera M., Pera M., de Bolos C., et al. Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats. J Gastrointest Surg 11 (2007) 869-874
71. Sarosi G., Brown G., Jaiswal K., et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus 21 (2008) 43-50
72. Glickman J.N., Chen Y.Y., Wang H.H., Antonioli D.A., and Odze R.D. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol 25 (2001) 569-578
73. Hanna S., Rastogi A., Weston A.P., et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 101 (2006) 1416-1420
74. Hamamoto Y., Endo T., Nosho K., Arimura Y., Sato M., and Imai K. Usefulness of narrow-band imaging endoscopy for diagnosis of Barrett's esophagus. J Gastroenterol 39 (2004) 14-20
75. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 131 (2006) 1392-1399
76. Paull A., Trier J.S., Dalton M.D., Camp R.C., Loeb P., and Goyal R.K. The histologic spectrum of Barrett's esophagus. N Engl J Med 295 (1976) 476-480
77. Harrison R., Perry I., Haddadin W., et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 102 (2007) 1154-1161
78. Eloubeidi M.A., and Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 94 (1999) 937-943
79. Kim S.L., Waring J.P., Spechler S.J., et al. Diagnostic inconsistencies in Barrett's esophagus. Department of Veterans Affairs Gastroesophageal Reflux Study Group. Gastroenterology 107 (1994) 945-949
80. Montgomery E., Bronner M.P., Goldblum J.R., et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 32 (2001) 368-378
81. Ormsby A.H., Petras R.E., Henricks W.H., et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 51 (2002) 671-676
82. Falk G.W., Ours T.M., and Richter J.E. Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointest Endosc 52 (2000) 197-203
83. Provenzale D., Schmitt C., and Wong J.B. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94 (1999) 2043-2053
84. Soni A., Sampliner R.E., and Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?. Am J Gastroenterol 95 (2000) 2086-2093
85. Inadomi J.M., Sampliner R., Lagergren J., Lieberman D., Fendrick A.M., and Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138 (2003) 176-186
86. Falk G.W., Chittajallu R., Goldblum J.R., et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 112 (1997) 1787-1797
87. Jobe B.A., Hunter J.G., Chang E.Y., et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am J Gastroenterol 101 (2006) 2693-2703
88. Lin O.S., Schembre D.B., Mergener K., et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux. Gastrointest Endosc 65 (2007) 577-583
89. Galmiche J.P., Sacher-Huvelin S., Coron E., et al. Screening for esophagitis and Barrett's esophagus with wireless esophageal capsule endoscopy: a multicenter prospective trial in patients with reflux symptoms. Am J Gastroenterol 103 (2008) 538-545
90. Gerson L., and Lin O.S. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol 5 (2007) 319-325
91. Rubenstein J.H., Inadomi J.M., Brill J.V., and Eisen G.M. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol 5 (2007) 312-318
92. Canto M.I., Setrakian S., Willis J., et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc 51 (2000) 560-568
93. Lim C.H., Rotimi O., Dexter S.P., and Axon A.T. Randomized crossover study that used methylene blue or random 4-quadrant biopsy for the diagnosis of dysplasia in Barrett's esophagus. Gastrointest Endosc 64 (2006) 195-199
94. Ragunath K., Krasner N., Raman V.S., Haqqani M.T., and Cheung W.Y. A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus. Endoscopy 35 (2003) 998-1003
95. Guelrud M., Herrera I., Essenfeld H., and Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 53 (2001) 559-565
96. Kara M.A., Ennahachi M., Fockens P., ten Kate F.J., and Bergman J.J. Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett's esophagus by using narrow band imaging. Gastrointest Endosc 64 (2006) 155-166
97. Sharma P., Bansal A., Mathur S., et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc 64 (2006) 167-175
98. Curvers W., Baak L., Kiesslich R., et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus. Gastroenterology 134 (2008) 670-679
99. Kara M.A., Peters F.P., ten Kate F.J., Van Deventer S.J., Fockens P., and Bergman J.J. Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. Gastrointest Endosc 61 (2005) 679-685
100. Poneros J.M., Brand S., Bouma B.E., Tearney G.J., Compton C.C., and Nishioka N.S. Diagnosis of specialized intestinal metaplasia by optical coherence tomography. Gastroenterology 120 (2001) 7-12
101. Isenberg G., Sivak Jr. M.V., Chak A., et al. Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett's esophagus: a prospective, double-blinded study. Gastrointest Endosc 62 (2005) 825-831
102. Kiesslich R., Gossner L., Goetz M., et al. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol 4 (2006) 979-987
103. Eloubeidi M.A., and Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 95 (2000) 1881-1887
104. Shaheen N.J., Green B., Medapalli R.K., et al. The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program. Gastroenterology 129 (2005) 429-436
105. Shaheen N.J., Dulai G.S., Ascher B., Mitchell K.L., and Schmitz S.M. Effect of a new diagnosis of Barrett's esophagus on insurance status. Am J Gastroenterol 100 (2005) 577-580
106. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120 (2001) 1630-1639
107. Reid B.J., Levine D.S., Longton G., Blount P.L., and Rabinovitch P.S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 (2000) 1669-1676
108. Zaninotto G., Parenti A.R., Ruol A., Costantini M., Merigliano S., and Ancona E. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg 87 (2000) 1102-1105
109. Heitmiller R.F., Redmond M., and Hamilton S.R. Barrett's esophagus with high-grade dysplasia: an indication for prophylactic esophagectomy. Ann Surg 224 (1996) 66-71
110. Konda V.J., Ross A.S., Ferguson M.K., et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?. Clin Gastroenterol Hepatol 6 (2008) 159-164
111. Williams V.A., Watson T.J., Herbella F.A., et al. Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome. J Gastrointest Surg 11 (2007) 1589-1597
112. Peyre C.G., DeMeester S.R., Rizzetto C., et al. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg 246 (2007) 665-671
113. Birkmeyer J.D., Siewers A.E., Finlayson E.V., et al. Hospital volume and surgical mortality in the United States. N Engl J Med 346 (2002) 1128-1137
114. Sampliner R.E., Hixson L.J., Fennerty M.B., and Garewal H.S. Regression of Barrett's esophagus by laser ablation in an anacid environment. Dig Dis Sci 38 (1993) 365-368
115. Berenson M.M., Johnson T.D., Markowitz N.R., Buchi K.N., and Samowitz W.S. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology 104 (1993) 1686-1691
116. Sampliner R.E., Fennerty B., and Garewal H.S. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 44 (1996) 532-535
117. Norberto L., Polese L., Angriman I., Erroi F., Cecchetto A., and D'Amico D.F. High-energy laser therapy of Barrett's esophagus: preliminary results. World J Surg 28 (2004) 350-354
118. Ackroyd R., Tam W., Schoeman M., Devitt P.G., and Watson D.I. Prospective randomized controlled trial of argon plasma coagulation ablation vs endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. Gastrointest Endosc 59 (2004) 1-7
119. Attwood S.E., Lewis C.J., Caplin S., Hemming K., and Armstrong G. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol 1 (2003) 258-263
120. Ackroyd R., Kelty C.J., Brown N.J., Stephenson T.J., Stoddard C.J., and Reed M.W. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 35 (2003) 496-501
121. Overholt B.F., Panjehpour M., and Halberg D.L. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 58 (2003) 183-188
122. Johnston M.H., Eastone J.A., Horwhat J.D., Cartledge J., Mathews J.S., and Foggy J.R. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc 62 (2005) 842-848
123. Sharma V.K., Wang K.K., Overholt B.F., et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 65 (2007) 185-195
124. Fleischer D.E., Overholt B.F., Sharma V.K., et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2·5-year follow-up. Gastrointest Endosc 68 (2008) 867-876
125. Ganz R.A., Overholt B.F., Sharma V.K., et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a US multicenter registry. Gastrointest Endosc 68 (2008) 35-40
126. Buttar N.S., Wang K.K., Lutzke L.S., Krishnadath K.K., and Anderson M.A. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 54 (2001) 682-688
127. Ell C., May A., Gossner L., et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 118 (2000) 670-677
128. Corley D.A., Kerlikowske K., Verma R., and Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (2003) 47-56
129. El-Serag H.B., Aguirre T.V., Davis S., Kuebeler M., Bhattacharyya A., and Sampliner R.E. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99 (2004) 1877-1883
130. Hillman L.C., Chiragakis L., Shadbolt B., Kaye G.L., and Clarke A.C. Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 180 (2004) 387-391
131. Parrilla P., de Haro L.M., Ortiz A., et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 237 (2003) 291-298
132. Corey K.E., Schmitz S.M., and Shaheen N.J. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 98 (2003) 2390-2394
133. Pohl H., and Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97 (2005) 142-146
134. Lagergren J., Bergstrom R., Lindgren A., and Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
135. Lao-Sirieix P., Lovat L., and Fitzgerald R.C. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res 13 (2007) 659-665
136. Keswani R.N., Noffsinger A., Waxman I., and Bissonnette M. Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 15 (2006) 1243-1249
137. Scheil-Bertram S., Lorenz D., Ell C., Sheremet E., and Fisseler-Eckhoff A. Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus. Mod Pathol 21 (2008) 961-967
138. Galipeau P.C., Li X., Blount P.L., et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4 (2007) e67
139. Jankowski J., and Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ 332 (2006) 1512